methyl (Z)-2-methyl-6-[(10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoate | 57303-62-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: methyl (Z)-2-methyl-6-[(10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoate
• CAS: 57303-62-5；117020-60-7
• 化学式: C₃₁H₄₈O₃
• 分子量: 468.72
• InChiKey: ZPPGZNDSKBSODV-SVTQZYHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS COMPRISING TRITERPENOIDS<br/>[FR] COMPOSITIONS COMPRENANT DES TRITERPÉNOÏDES
  申请人：REGENERA PHARMA LTD

  公开号：WO2017051423A1

  公开（公告）日：2017-03-30

  The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).

  该发明涉及包含至少一种三萜酸和至少一种中性三萜类化合物的组合物和配方，以及它们用于治疗阿尔茨海默病（AD）、帕金森病（PD）和血管性痴呆（VD）等疾病的用途。
• COMPOSITIONS COMPRISING TRITERPENOIDS
  申请人：REGENERA PHARMA LTD.

  公开号：US20190209582A1

  公开（公告）日：2019-07-11

  The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).